KRAS and colorectal carcinoma: In the present study, we investigated the therapeutic potential of the telomerase-specific replication-competent oncolytic adenoviruses OBP-301 and p53-armed OBP-702 for eliminating human CRC cells with differing KRAS/BRAF mutation status and microsatellite stability.